A phase i study of midostaurin and azacitidine in relapsed and elderly AML patients

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 7, 2015, Pages 428-432.e2

  Cooper, Brenda W ^a   Kindwall Keller, Tamila L ^a   Craig, Michael D ^a   Creger, Richard J ^a   Hamadani, Mehdi ^a   Tse, William W ^a   Lazarus, Hillard M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Azacitidine; Elderly AML; FLT3 inhibitor; Midostaurin

Indexed keywords

AZACITIDINE; CGP 52421; CGP 62221; DRUG METABOLITE; MIDOSTAURIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CD135 ANTIGEN; STAUROSPORINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PAIN; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITALIZATION; HUMAN; HYPOALBUMINEMIA; HYPONATREMIA; HYPOTENSION; LEUKEMIA REMISSION; LIVER TOXICITY; MALE; MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; MEDICATION COMPLIANCE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PNEUMONIA; SEPSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; GENETICS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTICENTER STUDY; MUTATION; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; STAUROSPORINE; TREATMENT OUTCOME;

EID: 84937521005     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.02.017     Document Type: Article

References (32)

1. F.R. Appelbaum, H. Gundacker, and D.R. Head Age and acute myeloid leukemia Blood 107 2006 3481 3485
2. S. Knipp, B. Hildebrandt, and A.A. Giagounidis Intensive chemotherapy is not recommended for patients with AML or high-risk MDS aged over 60 years with complex karyotype abnormalities Blood 104 2004 Abstract 72
3. P. Fenaux, G.J. Mufti, and E. Hellstrom-Lindberg Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia J Clin Oncol 28 2010 562 569
4. A. Quintas-Cardama, F. Ravandi, and T. Liu-Dumlao Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia Blood 120 2012 4840 4845
5. T. Prebet, Z. Sun, and M.E. Figueroa Prolonged administration of azacitidine with or without etinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E 1905 J Clin Oncol 32 2014 1242 1248
6. P. Strati, H.M. Kantarjian, A. Nazha, and et al. Early results of a phase I/II trial of midostaurin and 5-azacitidine for patients with acuter myeloid leukemia and myelodysplastic syndrome (abstract 3949) Blood 2013
7. S. Nand, M. Othus, and J.E. Godwin A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia Blood 122 2013 3432 3439
8. C.E. Carow, M. Levenstein, and S.H. Kaufmann Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias Blood 87 1996 1089 1096
9. C. Thiede, C. Steudel, and B. Mohr Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 99 2002 4326 4335
10. S.P. Whitman, K.J. Archer, L. Feng, and et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study Cancer Res 61 2001 7233 7239
11. H. Kiyoi, M. Towatari, and S. Yokota Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product Leukemia 12 1998 1333 1337
12. C.H. Brandis, B. Sargin, and M. Rode Constitutive activation of Akt by FLT3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation Cancer Res 65 2005 9643 9650
13. L.M. Kelly, Q. Liu, and J.L. Kutok FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model Blood 99 2002 310 318
14. E.V. Barry, J.J. Clark, and J. Cools Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin Blood 110 2007 4476 4479
15. M. Levis, A. Stine, and R. Pham Pharmacokinetic and pharmacodynamic studies of lestaurtinib (CEP701) and PKC 412: cytotoxicity is often dependent on non-flt3-mediated effects Blood 106 2005 Abstract 2463
16. T. Fischer, R.M. Stone, and D.J. Deangelo Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3 J Clin Oncol 28 2010 4339 4345
17. W. Fiedler, H. Serve, and H. Dohner A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia or not amenable to conventional therapy for the disease Blood 105 2005 986 993
18. S. Knapper, A.K. Burnett, and T. Littlewood A phase 2 trial of FLT3 inhibitor lestaurtinib (CEP701) as first line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy Blood 108 2006 3262 3270
19. J. Cortes, J. Foran, and D. Ghirdaladze AC 220: a potent selective second generation FLT3 receptor tyrosine inhibitor, in a first in human phase I AML study Blood 114 2009 Abstract 636
20. M. Levis, R. Pham, B.D. Smith, and D. Small In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects Blood 104 2004 1145 1150
21. Y. Kevin, M. Schitenheim, and A.M. O'Farrell Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells Blood 104 2004 4202 4209
22. I. Utz, M. Spitaler, and M. Rybczynska Reversal of multidrug resistance by staurosporine derivatives CGP41251 and CGP42700 Int J Cancer 77 1998 64 69
23. F. Ravandi, M.L. Alattar, and M.P. Grunwald Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation Blood 121 2013 4655 4662
24. S. Knapper, K.I. Mills, and A.F. Gilkes The effects of lestartinib (CEP 701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases Blood 108 2006 3494 3503
25. M. Levis, P. Brown, B. Douglas Smith, and et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic responses to FLT3 inhibitors Blood 108 2006 3477 3483
26. R.M. Stone, T. Fischer, and R. Paquette Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia Leukemia 26 2012 2061 2068
27. B.D. Cheson, J.M. Bennett, and K.J. Kopecky Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia J Clin Oncol 21 2003 4642 4649
28. E. Atallah, J. Cortes, S. O'Brien, and et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia Blood 110 2007 3547 3551
29. R. Van Gijn, O. Van Tellingen, and J.J. De Clippeleir Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potenial metabolites in human plasma by reversed-phase high-performance liquid chromoatography J Chromatogr B Biomed Appl 667 1995 269 276
30. J.J. Cornelissen, A. Gratwohl, and R.F. Schlenk The Europen LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach Nat Rev Clin Oncol 9 2012 579 590
31. M. Charlson, D.P. Szatrowski, J. Peterson, and J. Gold Validation of a combined comorbidity index J Clin Epidemiol 47 1994 1245 1251
32. O. Yin, C. Wang, and T. Lanza Pharmacokinetics and pharmacodynamic relationship in AML/MDS patients J Clin Oncol 26 15 suppl 2008 Abstract 7064